Risk Factors Update Summary
- Additional financing of approximately $15 million is needed to complete the Phase 2 trial for Berubicin.
- An additional $5.0 million is required to support near-term development of the WP1244/WP1874 program.
- Accumulated deficit increased from $50 million to $69 million since inception.
- The company's cash on hand is $0, down from $10 million as of December 31, 2023.
- The company's plan is funded into the latter half of the second quarter of 2024.
- The company's CEO serves as chairman, which may impact effectiveness.
- Non-compliance with Nasdaq's Listing Rule may lead to delisting, impacting the company negatively.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1729427&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.